Thermo Fisher unveils DNA/RNA extraction kit for haematological cancer research
A new sequential DNA/RNA isolation kit has been launched by Thermo Fisher Scientific, designed to streamline genomic analysis workflows in haematological cancer research. The MagMAX Sequential DNA/RNA kit enables concurrent extraction of DNA and RNA from a single sample, potentially accelerating research into blood-based malignancies.
The kit’s introduction comes at a significant time, with haematological cancers representing approximately 10% of new cancer cases annually. The technology allows clinical and translational researchers to conduct comprehensive genetic analyses of blood and bone marrow samples, specifically targeting the detection of genetic abnormalities associated with haematological malignancies.
Technical specifications
The MagMAX Sequential DNA/RNA kit incorporates both DNA and RNA isolation chemistries in a unified system, processing samples containing up to 15,000 white blood cells per microlitre. Notably, the system eliminates the requirement for separate red blood cell lysis steps, thereby reducing handling time and potential sources of error.
A key feature of the new kit is its ability to provide separate DNA and RNA eluates without additional processing steps. This eliminates the need for manual RNase treatment of total nucleic acid eluates when distinct DNA and RNA samples are required. The workflow has been designed to accommodate varying sample volumes and throughput requirements, offering flexibility for different laboratory settings.
Kevin Lowitz, vice president of sample preparation at Thermo Fisher Scientific, emphasised the kit’s utility in maximising sample information yield: “When researching blood cancer, it’s essential for scientists to extract the maximum amount of information from minimal sample volumes. Through this product innovation, we are supporting researchers and clinicians by providing a solution that allows for high-quality sequential isolation of genomic DNA and total RNA from a single blood or bone marrow sample.”
Target market applications
The technology is primarily targeted at specialty laboratories, large health system facilities, academic medical centres, and pharmaceutical companies engaged in personalised medicine research and clinical trials. The kit’s compact design considers laboratory storage constraints, whilst its automated capabilities aim to reduce hands-on time and accelerate data generation.
The system has been developed specifically for research applications and is not intended for diagnostic procedures.
For more information, visit: https://tinyurl.com/38wwj5jd
Digital issue: Please click here for more information
